Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz 

Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

The ALS Association

ALS Finding a Cure

Lysosomal Therapeutics

Morningside Group

ALS Investment Fund

Morningside Venture Investments

DRADS Capital

Woodline Partners

Marshall Wace

Perceptive Advisors

Polaris Founders Capital

Tybourne Capital Management

Verition Fund Management

683 CAPITAL

aMoon Fund

Belinda Termeer

Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com. 

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.

Today we announced the first participant dosed in the largest #progressivesupranuclearpalsy study to date. This Phase 3 #clinicaltrial for the treatment of #PSP will enroll approximately 600 participants across ~100 sites in the U.S., Canada, the EU, the UK, and Japan.
Read more: https://lnkd.in/enCfTTKU 

As 2023 draws to a close, we’re also reflecting on 10 years of Amylyx. We’d like to show our gratitude to the incredible determination of the #ALS and #neurodegenerative community, as well as our extraordinary global colleagues who show up every day with the shared mission of one day ending the suffering caused by neurodegenerative diseases.

At Amylyx, we’ve created a culture that uses unconventional thinking for unsolved problems. We learn from one another through our collective experience, and we share a connection in our common purpose. 
Does this sound like you? 
See our current openings: https://lnkd.in/eDq_3vK4 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory				4.88M -	24.05M 392.29%
average payables		2.90M -	10.50M 261.73%	32.00M 204.66%	34.34M 7.29%
average receivables				7.65M -	27.68M 261.66%
book value per share	-0.56 -	-1.45 160.86%	-2.74 88.54%	5.82 312.68%	6.19 6.35%
capex per share		-0.00 -	-0.01 94.55%	-0.04 575.46%	-0.02 58.94%
capex to depreciation		-151 -	-6.79 95.50%	-5.19 23.59%	-1.14 78.01%
capex to operating cash flow		0.00 -	0.00 14.69%	0.01 197.57%	-0.10 841.41%
capex to revenue				-0.11 -	-0.00 97.13%
cash per share	0.07 -	0.28 316.48%	2.57 818.01%	10.79 319.56%	5.31 50.84%
days of inventory on hand				1.19K -	549.82 53.85%
days payables outstanding				5.68K -	316.51 94.43%
days sales outstanding				251.31 -	38.39 84.72%
debt to assets	4.64 -	0.10 97.82%		0.02 -	0.01 48.94%
debt to equity	-0.59 -	-0.02 96.37%		0.02 -	0.01 46.96%
dividend yield
earnings yield	-0.02 -	-0.05 200.00%	-0.09 63.11%	-0.09 4.20%	0.05 152.11%
enterprise value	834.99M -	818.89M 1.93%	901.64M 10.10%	1.82B 101.94%	864.31M 52.53%
enterprise value over ebitda	-62.41 -	-21.15 66.11%	-10.90 48.44%	-9.04 17.07%	21.67 339.60%
ev to operating cash flow	-78.13 -	-22.31 71.44%	-12.05 45.98%	-10.12 16.02%	72.52 816.38%
ev to sales				81.90 -	2.27 97.23%
free cash flow per share	-0.23 -	-0.80 241.80%	-1.36 69.73%	-3.12 129.10%	0.15 104.89%
free cash flow yield	-0.01 -	-0.04 241.80%	-0.08 69.73%	-0.08 12.04%	0.01 112.28%
graham net net	-0.56 -	-1.48 164.04%	-2.08 40.52%	10.20 591.05%	4.81 52.88%
graham number	2.02 -	5.65 179.74%	9.90 75.37%	21.08 112.88%	9.90 53.01%
income quality	0.78 -	0.87 11.40%	0.85 1.99%	0.91 6.59%	0.24 73.32%
intangibles to total assets	0 -	0	0	0	0
interest coverage	-10.62 -	-17.05 60.49%		-46.92 -
interest debt per share	0.36 -	0.08 77.29%		0.18 -	0.06 66.49%
inventory turnover				0.31 -	0.66 116.68%
invested capital	-0.59 -	-0.02 96.37%		0.02 -	0.01 46.96%
market cap	823.13M -	830.34M 0.88%	997.75M 20.16%	2.16B 116.63%	1.03B 52.33%
net current asset value	-25.38M -	-67.19M 164.79%	-155.27M 131.09%	331.29M 313.36%	380.64M 14.90%
net debt to ebitda	-0.89 -	0.30 133.35%	1.16 293.03%	1.69 45.56%	-4.16 345.90%
net income per share	-0.33 -	-0.98 200.00%	-1.59 63.11%	-3.39 113.08%	0.70 120.76%
operating cash flow per share	-0.23 -	-0.80 240.40%	-1.35 69.63%	-3.07 126.99%	0.17 105.54%
payables turnover				0.06 -	1.15 1,695.86%
receivables turnover				1.45 -	9.51 554.64%
research and ddevelopement to revenue				4.20 -	0.34 91.99%
return on tangible assets	-4.60 -	-3.18 30.91%	-0.83 73.83%	-0.51 39.10%	0.10 118.79%
revenue per share				0.38 -	5.44 1,331.60%
roe	0.58 -	0.67 15.00%	0.58 13.49%	-0.58 200.19%	0.11 119.52%
roic	1.40 -	0.63 54.89%	0.55 13.70%	-0.57 204.70%	0.08 113.92%
sales general and administrative to revenue
shareholders equity per share	-0.56 -	-1.45 160.86%	-2.74 88.54%	5.82 312.68%	6.19 6.35%
stock based compensation to revenue				0.98 -	0.10 90.01%
tangible asset value	-25.36M -	-66.72M 163.14%	-151.17M 126.55%	340.61M 325.32%	433.43M 27.25%
tangible book value per share	-0.56 -	-1.45 160.86%	-2.74 88.54%	5.82 312.68%	6.19 6.35%
working capital	-1.33M -	6.31M 575.73%	84.11M 1,232.39%	335.52M 298.89%	382.62M 14.04%

COM:AMYLYX

Amylyx Pharmaceuticals, Inc.

Last Close

5.19

22/11 21:00

Market Cap

361.25M

Beta: -

Volume Today

831.95K

Avg: -

Preview